Cargando…

In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment

Tractable experimental model that accounts for inter-tumor molecular heterogeneity is a key element of anti-cancer drug development. Hepatocellular carcinoma is known to exhibit highly heterogeneous molecular aberrations across the tumors, including somatic genetic and epigenetic alterations. Previo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirschfield, Hadassa, Bian, C Billie, Higashi, Takaaki, Nakagawa, Shigeki, Zeleke, Tizita Z, Nair, Venugopalan D, Fuchs, Bryan C, Hoshida, Yujin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992986/ https://www.ncbi.nlm.nih.gov/pubmed/29303513 http://dx.doi.org/10.1038/emm.2017.164

Ejemplares similares

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Molecular heterogeneity in hepatocellular carcinoma
por: Zhu, Shijia, et al.
Publicado: (2018)

Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges
por: Li, Shen, et al.
Publicado: (2020)

Hepatitis C virus-induced hepatocellular carcinoma
por: Goossens, Nicolas, et al.
Publicado: (2015)

Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk
por: Kubota, Naoto, et al.
Publicado: (2020)

Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis
por: Goossens, Nicolas, et al.
Publicado: (2017)

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer
por: Erstad, Derek J., et al.
Publicado: (2017)

Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma
por: Baumert, Thomas F., et al.
Publicado: (2019)

Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis
por: Li, Shen, et al.
Publicado: (2018)

Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets
por: Hoshida, Yujin, et al.
Publicado: (2007)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019)

The Breast Cancer Single-Cell Atlas: Defining cellular heterogeneity within model cell lines and primary tumors to inform disease subtype, stemness, and treatment options
por: Dave, Arpit, et al.
Publicado: (2023)

Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment
por: Hoshida, Yujin
Publicado: (2010)

Disseminative Recurrence Signature for Hepatocellular Carcinoma From Nonalcoholic Fatty Liver Disease
por: FUJIWARA, N., et al.
Publicado: (2023)

A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery
por: Crouchet, Emilie, et al.
Publicado: (2021)

Comparative Epigenomic Profiling of the DNA Methylome in Mouse and Zebrafish Uncovers High Interspecies Divergence
por: Zhang, Chi, et al.
Publicado: (2016)

Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis
por: Ma, Siyuan, et al.
Publicado: (2018)

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma
por: Finkin, Shlomi, et al.
Publicado: (2015)

Diverse Basis of β-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis
por: Okabe, Hirohisa, et al.
Publicado: (2016)

Survival analysis tools in genomics research
por: Chen, Xintong, et al.
Publicado: (2014)

Prognostic gene signature profiles of hepatitis C-related early-stage liver cirrhosis
por: Venkatesh, Anu, et al.
Publicado: (2014)

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma
por: Kancherla, Venkatesh, et al.
Publicado: (2018)

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells
por: Hicks, Daniel F., et al.
Publicado: (2017)

Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance
por: Goossens, Nicolas, et al.
Publicado: (2015)

Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging
por: Hectors, Stefanie J., et al.
Publicado: (2017)

Reactive lymphoid hyperplasia of the liver requires differential diagnosis of hepatocellular carcinoma
por: Higashi, Takaaki, et al.
Publicado: (2015)

Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation
por: Crouchet, Emilie, et al.
Publicado: (2022)

Chest imaging in pregnant patients with COVID-19: Recommendations, justification, and optimization
por: Nair, Anirudh Venugopalan, et al.
Publicado: (2022)

MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation
por: Yip, Shun H., et al.
Publicado: (2019)

Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature
por: Kim, Myung‐Ho, et al.
Publicado: (2022)

The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy
por: Kim, Rosa S., et al.
Publicado: (2016)

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
por: Jühling, Frank, et al.
Publicado: (2021)

An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma
por: Tsuda, Yasuhiro, et al.
Publicado: (2012)

Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer
por: Sakamoto, Keita, et al.
Publicado: (2015)

Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis
por: King, Lindsay Y., et al.
Publicado: (2014)

Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine
por: Kishikawa, Takahiro, et al.
Publicado: (2015)

Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared With Corticolimbic Alzheimer Disease Subtypes
por: Boon, Baayla D.C., et al.
Publicado: (2023)

Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis
por: Rocha, Chiara, et al.
Publicado: (2023)

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
por: Asgharpour, Amon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uv8hahibceo2m7mb0115m0sdqb